Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma

European Journal of Cancer

Volumn 46, Issue 15, 2010, Pages 2837-2848

  Perrone, Federica ^a   Jocoll, Genny ^a   Pennati, Marzia ^a   Deraco, Marcello ^a   Baratti, Dario ^a   Brich, Silvia ^a   Orsenigo, Marta ^a   Tarantino, Eva ^a   De Marco, Cinzia ^a   Bertan, Claudia ^a   Cabras, Antonello ^a   Bertulli, Rossella ^a   Pierotti, Marco Alessandro ^a   Zaffaroni, Nadia ^a   Pilotti, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Diffuse malignant peritoneal mesothelioma; EGFR; mTOR; p16; PDGFRB

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CALRETININ; CASPASE 3; CLAUDIN 4; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; GEFITINIB; INITIATION FACTOR 4E BINDING PROTEIN 1; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PODOPLANIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; S6 KINASE; SORAFENIB; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; AGED; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN STO; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE SEQUENCE; DRUG POTENTIATION; DRUG TARGETING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FLUORESCENCE MICROSCOPY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOPRECIPITATION; MALE; MALIGNANT MESOTHELIOMA; MUTATIONAL ANALYSIS; NONHUMAN; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADULT; AGED; APOPTOSIS; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, P16; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MIDDLE AGED; MUTATION; PLEURAL NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA;

EID: 77957203611     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.06.130     Document Type: Article

References (38)

1. M. Deraco, D. Bartlett, S. Kusamura, and D. Baratti Consensus statement on peritoneal mesothelioma J Surg Oncol 98 2008 268 272
2. T.D. Yan, M. Deraco, and D. Baratti Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience J Clin Oncol 27 2009 6237 6242
3. G. Carteni, C. Manegold, G.M. Garcia, and S. Siena Malignant peritoneal mesothelioma - results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent Lung Cancer 64 2009 211 218
4. D. Baratti, S. Kusamura, and A.D. Cabras Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) Ann Surg Oncol 16 2009 463 472
5. D. Nonaka, S. Kusamura, and D. Baratti Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution Cancer 104 2005 2181 2188 (Pubitemid 41579965)
6. S. Chiosea, A. Krasinskas, and P.T. Cagle Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas Mod Pathol 21 2008 742 747 (Pubitemid 351744840)
7. P.B. Illei, V.W. Rusch, and M.F. Zakowski And Ladanyi M Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas Clin Cancer Res 9 2003 2108 2113
8. M. Deraco, D. Nonaka, and D. Baratti Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion Ann Surg Oncol 13 2006 229 237 (Pubitemid 43157418)
9. J.K. Trupiano, K.R. Geisinger, and M.C. Willingham Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers Mod Pathol 17 2004 476 481
10. K.J. Butnor, J.L. Burchette, T.A. Sporn, S.P. Hammar, and V.L. Roggli The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature Arch Pathol Lab Med 128 2004 538 543
11. A.C. Borczuk, R.N. Taub, and M. Hesdorffer P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma Clin Cancer Res 11 2005 3303 3308 (Pubitemid 40627879)
12. R. Villa, M.G. Daidone, and R. Motta Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma Clin Cancer Res 14 2008 4134 4140
13. N. Zaffaroni, A. Costa, and M. Pennati Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma Cell Oncol 29 2007 453 466 (Pubitemid 350136500)
14. G. Giaccone, P. Zatloukal, and J. Roubec Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer J Clin Oncol 27 2009 4481 4486
15. A.C. Borczuk, G.C.A. Cappellini, and H.K. Kim Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors Oncogene 26 2007 610 617
16. H. Kothmaier, F. Quehenberger, and I. Halbwedl EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors Thorax 63 2008 345 351 (Pubitemid 351497948)
17. A.W. Langerak, P.A. De Laat, and C.A. Van Der Linden-Van Beurden Et al.Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo J Pathol 178 1996 151 160 (Pubitemid 26057966)
18. F. Roberts, C.M. Harper, I. Downie, and R.A. Burnett Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies Am J Clin Pathol 116 2001 253 262 (Pubitemid 33044331)
19. J.M. Foster, Z. Gatalica, S. Lilleberg, G. Haynatzki, and B.W. Loggie Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma Ann Surg Oncol 16 2009 152 158
20. E. Tamborini, L. Bonadiman, and A. Greco Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma Clin Cancer Res 10 2004 938 943 (Pubitemid 38198893)
21. F. Perrone, L. Da Riva, and M. Orsenigo PDGFRA, PDGFRB, EGFR, and downstream signalling activation in malignant peripheral nerve sheath tumor Neuro Oncol 11 2009 725 736
22. M.S. Lagonigro, E. Tamborini, and T. Negri PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma J Pathol 208 2006 615 623
23. S. Stacchiotti, E. Tamborini, and A. Marrari Response to sunitinib malate in advanced alveolar soft part sarcoma Clin Cancer Res 15 2009 1096 1104
24. F. Perrone, S. Suardi, and E. Pastore Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma Clin Cancer Res 12 2006 6643 6651 (Pubitemid 44876832)
25. E. Tamborini, P. Casieri, and F. Miselli Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas J Pathos 212 2007 227 235 (Pubitemid 46860154)
26. E. Tamborini, F. Miselli, and T. Negri Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas Clin Cancer Res 12 2006 6920 6928 (Pubitemid 44974484)
27. F. Perrone, A. Lampis, and M. Orsenigo PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients Ann Oncol 20 2009 84 90
28. P. Skehan, R. Storeng, and Scudiero New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 82 1990 1107 1112 (Pubitemid 20213250)
29. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
30. C. Porta, C. Paglino, I. Imarisio, and E. Ferraris Sorafenib tosylate in advanced kidney cancer: past, present and future Anticancer Drugs 20 2009 409 415
31. R. Govindan, R.A. Kratzke, and J.E. Herndon 2nd Gefitinib in patients with malignant mesothelioma: a phase II study by the cancer and leukemia group B Clin Cancer Res 11 2005 2300 2304 (Pubitemid 40490190)
32. L.L. Garland, C. Rankin, and D.R. Gandara Phase II study of erlotinib in patients with malignant pleural mesothelioma: a southwest oncology group study Clin Oncol 25 2007 2406 2413 (Pubitemid 46999211)
33. C. Porta, L. Mutti, and G. Tassi Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma Cancer Chemother Pharmacol 59 2007 149 150 (Pubitemid 44796113)
34. A. Mathy, P. Baas, O. Dalesio, and N. van Zandwijk Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial Lung Cancer 50 2005 83 86 (Pubitemid 41297473)
35. M.A. Pierotti, T. Negri, and E. Tamborini Targeted therapies: the rare cancer paradigm Mol Oncol 4 2010 19 37
36. K. Kawaguchi, H. Murakami, and T. Taniguchi Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells Carcinogenesis 30 2009 1097 1105
37. B.D. Manning, M.N. Logsdon, and A.I. Lipovsky Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2 Genes Dev 19 2005 1773 1778
38. A. Carracedo, L. Ma, and J. Teruya-Feldstein Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J Clin Invest 118 2008 3065 3074